Latham & Watkins Advises Zerigo Health in Its US$43 Million Series B

Zerigo Health, which delivers the only connected light therapy solution for treating chronic skin conditions at home or on the go, has announced a US$43 million Series B investment led by 7wireVentures, joined by General Catalyst, Dragoneer, Cigna Ventures, Leverage Health Solutions, and Leaps by Bayer. The round also included participation by existing investors including SV Health Investors, H.I.G. Capital, and Bluestem Capital. This round will allow Zerigo Health to respond to the increasing demand for its innovative connected chronic skin condition solution for the over 40 million Americans living with psoriasis, vitiligo, and eczema.

Latham & Watkins LLP represents Zerigo Health in the financing with a corporate deal team led by San Diego partner Cheston Larson, with San Diego associates Christian Hollweg and Madelyn Tarr and New York associate Teddy Ellison.